Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments
“Our proprietary intranasal platform has the potential to enhance drug delivery bioavailability. We believe that intranasal delivery has the potential to improve patient outcomes by providing a ...
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Hosted on MSN2mon
Polyrizon's Retail Following Booms As Biotech Stock Triples On Manufacturing Deal For Allergy Blocker Trial
Shares of Polyrizon skyrocketed more than 200% to an all-time high on Wednesday, making it the top biotech stock with the most new followers on Stocktwits in the past 24 hours.
Nasdaq4d
Polyrizon Ltd. Initiates Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdoses
Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the start of preclinical studies for its intranasal Naloxone product aimed at treating opioid overdoses. Collaborating ...
Morningstar4d
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...
Hosted on MSN1mon
Polyrizon files patent for nasal drug delivery tech
Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.
Nasdaq2d
Polyrizon Ltd. Files Annual Report on Form 20-F for Fiscal Year 2024
Polyrizon's filing of its Annual Report on Form 20-F with the SEC reflects compliance with regulatory requirements, which can enhance the company's credibility and transparency to investors.
Investing4d
Polyrizon begins preclinical studies for nasal opioid overdose treatment
RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech firm with a market capitalization of $3.46 million focused on developing nasal hydrogels, has launched preclinical studies for ...
WATE 6 On Your Side1mon
Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform
Raanana, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of ...
WJHL-TV1mon
Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company ...
manilatimes4d
Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform
Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...